Non-Motor and Motor Features in LRRK2 Transgenic Mice

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Bichler, Zoë ^a,b   Lim, Han Chi ^a   Zeng, Li ^a,b   Tan, Eng King ^a,b,c  

^a NATIONAL NEUROSCIENCE INSTITUTE   (Singapore)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

^c SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

LEUCINE RICH REPEAT KINASE 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; CONTROLLED STUDY; DEPRESSION; DIGESTIVE SYSTEM FUNCTION DISORDER; GENE OVEREXPRESSION; HYPOKINESIA; LEARNING; LONGITUDINAL STUDY; LRRK2 GENE; MALE; MEMORY; MOUSE; MOUSE MUTANT; NOCICEPTION; NONHUMAN; PARKINSON DISEASE; PHENOTYPE; SMELLING; TRANSGENIC MOUSE;

AGE FACTORS; ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; DEPRESSION; DISEASE MODELS, ANIMAL; GASTROINTESTINAL DISEASES; GENE EXPRESSION; LEARNING; MALE; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; MUTATION; PARKINSON DISEASE; PHENOTYPE; PROTEIN-SERINE-THREONINE KINASES;

EID: 84880789550     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070249     Document Type: Article

References (65)

1. Schapira AH, Jenner P, (2011) Etiology and pathogenesis of Parkinson's disease. Mov Disord 26: 1049-1055.
2. Chaudhuri KR, Odin P, Antonini A, Martinez-Martin P, (2011) Parkinson's disease: The non-motor issues. Parkinsonism Relat Disord 17: 717-23.
3. Schapira A (2011) Parkinson's disease. New york: Oxford University Press. 116p.
4. Healy DG, Falchi M, O'Sullivan SS, Bonifati V, Durr A, et al. (2008) Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 7: 583-590.
5. Blonder LX, Slevin JT, (2011) Emotional dysfunction in Parkinson's disease. Behav Neurol 24: 201-217.
6. Martinez-Martin P, Damian J, (2010) Parkinson disease: Depression and anxiety in Parkinson disease. Nat Rev Neurol 6: 243-245.
7. Chaudhuri KR, Odin P, (2010) The challenge of non-motor symptoms in Parkinson's disease. Prog Brain Res 184: 325-341.
8. Meissner WG, Frasier M, Gasser T, Goetz CG, Lozano A, et al. (2011) Priorities in Parkinson's disease research. Nat Rev Drug Discov 10: 377-393.
9. Rodriguez-Oroz MC, Jahanshahi M, Krack P, Litvan I, Macias R, et al. (2009) Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms. Lancet Neurol 8: 1128-1139.
10. Wu Y, Le W, Jankovic J, (2011) Preclinical biomarkers of Parkinson disease. Arch Neurol 68: 22-30.
11. Sherer TB, (2011) Biomarkers for Parkinson's disease. Sci Transl Med 3: 79ps14.
12. Tan EK, Peng R, Teo YY, Tan LC, Angeles D, et al. (2010) Multiple LRRK2 variants modulate risk of Parkinson disease: a Chinese multicenter study. Hum Mutat 31: 561-568.
13. Kumari U, Tan EK, (2009) LRRK2 in Parkinson's disease: genetic and clinical studies from patients. FEBS J 276: 6455-6463.
14. Gandhi PN, Chen SG, Wilson-Delfosse AL, (2009) Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease. J Neurosci Res 87: 1283-1295.
15. Simon-Sanchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, et al. (2009) Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 41: 1308-1312.
16. Satake W, Nakabayashi Y, Mizuta I, Hirota Y, Ito C, et al. (2009) Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet 41: 1303-1307.
17. Tan EK, Zhao Y, Skipper L, Tan MG, Di Fonzo A, et al. (2007) The LRRK2 Gly2385Arg variant is associated with Parkinson's disease: genetic and functional evidence. Hum Genet 120: 857-863.
18. Ardayfio P, Moon J, Leung KK, Youn-Hwang D, Kim KS, (2008) Impaired learning and memory in Pitx3 deficient aphakia mice: a genetic model for striatum-dependent cognitive symptoms in Parkinson's disease. Neurobiol Dis 31: 406-412.
19. Ekstrand MI, Galter D, (2009) The MitoPark Mouse- an animal model of Parkinson's disease with impaired respiratory chain function in dopamine neurons. Parkinsonism Relat Disord 15Suppl 3: S185-188.
20. Dawson TM, Ko HS, Dawson VL, (2010) Genetic animal models of Parkinson's disease. Neuron 66: 646-661.
21. Li T, Yang D, Sushchky S, Liu Z, Smith WW, (2011) Models for LRRK2-Linked Parkinsonism. Parkinsons Dis 2011: 942412.
22. Li Y, Liu W, Oo TF, Wang L, Tang Y, et al. (2009) Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat Neurosci 12: 826-828.
23. Melrose HL, Dachsel JC, Behrouz B, Lincoln SJ, Yue M, et al. (2010) Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice. Neurobiol Dis 40: 503-517.
24. Li X, Patel JC, Wang J, Avshalumov MV, Nicholson C, et al. (2010) Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S. J Neurosci 30: 1788-1797.
25. Ramonet D, Daher JP, Lin BM, Stafa K, Kim J, et al. (2011) Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS One 6: e18568.
26. Maekawa T, Mori S, Sasaki Y, Miyajima T, Azuma S, et al. (2012) The I2020T Leucine-rich repeat kinase 2 transgenic mouse exhibits impaired locomotive ability accompanied by dopaminergic neuron abnormalities. Mol Neurodegener 7: 15.
27. Herzig MC, Bidinosti M, Schweizer T, Hafner T, Stemmelen C, et al. (2012) High LRRK2 levels fail to induce or exacerbate neuronal alpha-synucleinopathy in mouse brain. PLoS One 7: e36581.
28. Wey MC, Fernandez E, Martinez PA, Sullivan P, Goldstein DS, et al. (2012) Neurodegeneration and motor dysfunction in mice lacking cytosolic and mitochondrial aldehyde dehydrogenases: implications for Parkinson's disease. PLoS One 7: e31522.
29. Ruiz-Martinez J, Gorostidi A, Goyenechea E, Alzualde A, Poza JJ, et al. (2011) Olfactory deficits and cardiac 123I-MIBG in Parkinson's disease related to the LRRK2 R1441G and G2019S mutations. Mov Disord 26: 2026-2031.
30. Hinkle KM, Yue M, Behrouz B, Dachsel JC, Lincoln SJ, et al. (2012) LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors. Mol Neurodegener 7: 25.
31. Tong Y, Pisani A, Martella G, Karouani M, Yamaguchi H, et al. (2009) R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. Proc Natl Acad Sci U S A 106: 14622-14627.
32. Beal MF, (2010) Parkinson's disease: a model dilemma. Nature 466: S8-10.
33. Gillardon F, Schmid R, Draheim H, (2012) Parkinson's disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity. Neuroscience 208: 41-48.
34. Tjolsen A, Berge OG, Hunskaar S, Rosland JH, Hole K, (1992) The formalin test: an evaluation of the method. Pain 51: 5-17.
35. Crabtree DM, Zhang J, (2012) Genetically engineered mouse models of Parkinson's disease. Brain Res Bull 88: 13-32.
36. Khedr EM, El Fetoh NA, Khalifa H, Ahmed MA, El Beh KM, (2013) Prevalence of non motor features in a cohort of Parkinson's disease patients. Clin Neurol Neurosurg 115: 673-7.
37. Chaudhuri KR, Odin P, Antonini A, Martinez-Martin P, (2011) Parkinson's disease: the non-motor issues. Parkinsonism Relat Disord 17: 717-723.
38. Royle SJ, Collins FC, Rupniak HT, Barnes JC, Anderson R, (1999) Behavioural analysis and susceptibility to CNS injury of four inbred strains of mice. Brain Res 816: 337-349.
39. Voikar V, Koks S, Vasar E, Rauvala H, (2001) Strain and gender differences in the behavior of mouse lines commonly used in transgenic studies. Physiol Behav 72: 271-281.
40. Brown RE, Wong AA, (2007) The influence of visual ability on learning and memory performance in 13 strains of mice. Learn Mem 14: 134-144.
41. Tillerson JL, Caudle WM, Parent JM, Gong C, Schallert T, et al. (2006) Olfactory discrimination deficits in mice lacking the dopamine transporter or the D2 dopamine receptor. Behav Brain Res 172: 97-105.
42. Johansen KK, White LR, Farrer MJ, Aasly JO, (2011) Subclinical signs in LRRK2 mutation carriers. Parkinsonism Relat Disord 17: 528-532.
43. Marti-Masso JF, Ruiz-Martinez J, Bolano MJ, Ruiz I, Gorostidi A, et al. (2009) Neuropathology of Parkinson's disease with the R1441G mutation in LRRK2. Mov Disord 24: 1998-2001.
44. Zambito Marsala S, Tinazzi M, Vitaliani R, Recchia S, Fabris F, et al. (2011) Spontaneous pain, pain threshold, and pain tolerance in Parkinson's disease. J Neurol 258: 627-633.
45. Mogil JS, Lichtensteiger CA, Wilson SG, (1998) The effect of genotype on sensitivity to inflammatory nociception: characterization of resistant (A/J) and sensitive (C57BL/6J) inbred mouse strains. Pain 76: 115-125.
46. Mogil JS, Wilson SG, Bon K, Lee SE, Chung K, et al. (1999) Heritability of nociception I: responses of 11 inbred mouse strains on 12 measures of nociception. Pain 80: 67-82.
47. Quock RM, Mueller JL, Vaughn LK, (1993) Strain-dependent differences in responsiveness of mice to nitrous oxide (N2O) antinociception. Brain Res 614: 52-56.
48. Poulopoulos M, Levy OA, Alcalay RN, (2012) The neuropathology of genetic Parkinson's disease. Mov Disord 27: 831-842.
49. Lad HV, Liu L, Paya-Cano JL, Parsons MJ, Kember R, et al. (2010) Behavioural battery testing: evaluation and behavioural outcomes in 8 inbred mouse strains. Physiol Behav 99: 301-316.
50. Petrovitch H, Abbott RD, Ross GW, Nelson J, Masaki KH, et al. (2009) Bowel movement frequency in late-life and substantia nigra neuron density at death. Mov Disord 24: 371-376.
51. Ren G, Xin S, Li S, Zhong H, Lin S, (2011) Disruption of LRRK2 does not cause specific loss of dopaminergic neurons in zebrafish. PLoS One 6: e20630.
52. Devine MJ, Kaganovich A, Ryten M, Mamais A, Trabzuni D, et al. (2011) Pathogenic LRRK2 mutations do not alter gene expression in cell model systems or human brain tissue. PLoS One 6: e22489.
53. Gao HM, Kotzbauer PT, Uryu K, Leight S, Trojanowski JQ, et al. (2008) Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. J Neurosci 28: 7687-7698.
54. Norris EH, Uryu K, Leight S, Giasson BI, Trojanowski JQ, et al. (2007) Pesticide exposure exacerbates alpha-synucleinopathy in an A53T transgenic mouse model. Am J Pathol 170: 658-666.
55. Smith WW, Liu Z, Liang Y, Masuda N, Swing DA, et al. (2010) Synphilin-1 attenuates neuronal degeneration in the A53T alpha-synuclein transgenic mouse model. Hum Mol Genet 19: 2087-2098.
56. Peng J, Oo ML, Andersen JK, (2010) Synergistic effects of environmental risk factors and gene mutations in Parkinson's disease accelerate age-related neurodegeneration. J Neurochem 115: 1363-1373.
57. Desplats P, Patel P, Kosberg K, Mante M, Patrick C, et al. (2012) Combined exposure to Maneb and Paraquat alters transcriptional regulation of neurogenesis-related genes in mice models of Parkinson's disease. Mol Neurodegener 7: 49.
58. Tan EK, Reichmann H, (2010) Causes of Parkinson's disease: genetics, environment and pathogenesis. In: Schapira AHV, editor. Parkinson's Disease. Oxford: Oxford University Press. 5: 15.
59. Vlajinac H, Sipetic S, Marinkovic J, Ratkov I, Maksimovic J, et al. (2013) The stressful life events and Parkinson's disease: a case-control study. Stress Health 29: 50-55.
60. Burbulla LF, Kruger R, (2011) Converging environmental and genetic pathways in the pathogenesis of Parkinson's disease. J Neurol Sci 306: 1-8.
61. Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, et al. (2012) A call for transparent reporting to optimize the predictive value of preclinical research. Nature 490: 187-191.
62. Potter M, Yuan C, Ottenritter C, Mughal M, van Praag H, (2010) Exercise is not beneficial and may accelerate symptom onset in a mouse model of Huntington's disease. PLoS Curr 2: RRN1201.
63. Fleming SM, Tetreault NA, Mulligan CK, Hutson CB, Masliah E, et al. (2008) Olfactory deficits in mice overexpressing human wildtype alpha-synuclein. Eur J Neurosci 28: 247-256.
64. Branchi I, Bichler Z, Minghetti L, Delabar JM, Malchiodi-Albedi F, et al. (2004) Transgenic mouse in vivo library of human Down syndrome critical region 1: association between DYRK1A overexpression, brain development abnormalities, and cell cycle protein alteration. J Neuropathol Exp Neurol 63: 429-440.
65. Taylor TN, Caudle WM, Shepherd KR, Noorian A, Jackson CR, et al. (2009) Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity. J Neurosci 29: 8103-8113.